CanSino Biologics

CompanyChinaFounded 2009

CanSino Biologics develops one asset, in phase 3 (recombinant zoster vaccine in cardiovascular disease). Mostly vaccine acting on inflammation; based in China, founded in 2009.

1
Asset
Furthest stage: Phase 3; 1
Trial: 1
Signal

Pipeline

1

recombinant zoster vaccine
Induces immunity against varicella-zoster virus using recombinant glycoprotein E with an adjuvant.
Phase 3, Vaccine, Inflammation, cardiovascular disease, herpes zoster

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms2
Trials1
Signals4
Similar companies6